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Specific IgE Testing (RAST)
Reto Crameri
Abstract The diagnosis of allergic diseases is based on a combination of clinical
history, physical examination, in vivo challenges, and in vitro test methods for the
detection of allergen-specific IgE antibodies in the serum of patients. In spite of the
fact that the determination of allergen-specific IgE in serum is widely used in daily
clinical practice, one should be aware that such determinations, although useful for
routine screening of possible allergies, are not sufficient to diagnose the disease.
Clinical history and provocation tests should always be considered to confirm an
allergy indicated by elevated allergen-specific IgE levels in serum. This specially
applies to the diagnosis of mould allergy in general, and of Aspergillus fumigatus-
related allergic complications in particular.
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1 Introduction
The first documented clinical history of an allergy was reported by Dr. John Bostock
which recorded his own case history as first complete description of catarrus aes-
tivus or hay fever in 1819 [1], followed by the description of pollen grains as
causative agents for allergic reactions by Charles Blackley in 1873 [2]. The term
“allergy” is derived from the Greek words allos (other) and ergon (reaction) and
was proposed by the Viennese paediatrician Clemens von Pirquet in 1906. He
described allergy as “an altered capacity of the body to react to a foreign substance”
[3]. In 1921 Prausnitz and Küstner discovered a transferable tissue-sensitising fac-
tor in serum [4], which was then identified as a self-protein representing a new
immunoglobulin subclass (immunoglobulin E or IgE) by Johansen and Bennich [5]
and Ishizaka et al. in 1967 [6]. The pivotal discovery of IgE as a mediator of allergic
disease marks the beginning of modern allergology.
Like other immunoglobulins, IgE consists of two light and two heavy chains
(ε-isotype) and can be produced in two forms by alternative splicing: a secreted
and a membrane-bound form [7]. In sensitised atopic individuals, allergen exposure
induces cross-linking of high-affinity FcRI receptor-bound IgE on effector cells
and, thus, immediate release of anaphylactogenic mediators [8]. Normally, IgE is
a tissue-bound molecule which is, however, also present in low concentration in
serum, in equilibrium with that bound to effector cells [9]. The soluble form of
human IgE consists of two identical light chains (either kappa or lambda) that are
indistinguishable from the light chains of the other human immunoglobulins. In
contrast, the two heavy -chains contain a variable domain (VH) and four isotype-
specific structural domains (C1, C2, C3, and C4) [10]. The structural differ-
ences between the IgE constant domains and the constant domains of all other
immunoglobulin classes, allows the development of highly specific tests for the
detection of serum IgE.
2 Assays for the In Vitro Determination of Specific IgE
Antibodies
The prototype for the in vitro measurement of the serum IgE concentration was
the radioallergosorbent test (RAST), first described in 1967 [11]. The original
RAST employed a paper disc as solid phase to covalently immobilize the aller-
gen (allergosorbent), used to capture allergen-specific antibodies of all isotypes
(mainly IgG, IgA, and IgE) from serum samples. Following different washing pro-
cedures to remove unbound serum proteins and antibodies, bound IgE was detected
with 125I-labelled polyclonal anti-human IgE. Results were reported in classes or
in arbitrary units (PRU/ml) by interpolation from a reference standard curve [12].
Although not quantitative, the so-called Phadebas-RAST commercially introduced
in 1974 by Pharmacia (Uppsala, Sweden) under the trademark “RAST”, represented
a milestone for the laboratory diagnosis of atopy. Whilst the terms “RAST” and
“RAST class” are still widely used in clinical practice to refer to the presence of
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allergen-specific IgE in serum, the original radioallergosorbent test has been made
obsolete by advances in assay technology.
Modern immunoassays for the detection of allergen-specific IgE have undergone
relevant improvements, including substitution of the radio-labelled polyclonal anti-
bodies with enzyme-labelled monoclonal detection antibodies [13], the develop-
ment of solid phase systems with higher allergen binding capacities [14], and the
introduction of fully automated devices [15]. Most of the currently used IgE detec-
tion systems are calibrated against the World Health Organization (WHO) Standard
72/502, and can be considered “quantitative” assays [12]. Results of quantitative
assays are expressed in UA or kUA/l where 1 UA IgE antibody corresponds to 1 IU
IgE directly convertible to 2.42 ng of IgE [16]. However, the quantity of allergen-
specific IgE measured in serum depends on many factors, especially from the quality
of the extract immobilised to the solid phase (see below), and might be subject to
huge variations between different test systems.
3 Problems Related to Allergen Extracts and Mould Extracts
in Particular
Allergen extracts prepared from natural sources are complex mixtures containing
allergenic and non-allergenic proteins. In the normal case the single allergens will
constitute a minor component of the extract compared to the non allergenic proteins,
because only a minority of the proteins are able to induce a switch to IgE production
[17]. These extracts are subject to batch-to-batch variation due to different reasons
like extraction procedure used, biochemical stability of the allergens, protease con-
tent, and storage [18]. Many efforts have been undertaken to standardize allergen
extracts [19] but only a few allergen extract preparations, out of hundreds com-
mercially available, have been approved by the WHO for the use as international
standards [20]. Recently, the WHO-IUIS Allergen Standardization Committee has
taken an initiative, founded by the European Union, to develop certified reference
materials based on purified natural and recombinant allergens [21]. The aim of the
project is to develop certified reference materials to be used to standardize allergen
extracts. Such material would definitively help to calibrate the internal reference
preparations used in different laboratories of manufacturers, research groups, and
control authorities against a commonly accepted reference extract.
Special problems have been encountered in the standardisation of fungal extracts.
The raw material used to prepare fungal extracts derives from fungal cultures grown
in complex media. Depending on strain used, culture conditions and time, huge
variations in the allergenic potency between different commercial products have
been detected [22, 23]. The problem is best exemplified by a study which analysed
different commercial fungal extract for their major allergen content using highly
specific monoclonal antibodies [24]. The concentration of the major allergen Alt a
1 in Alternaria alternata extracts from 8 companies ranged from less than 0.01 to
6.09 μg/ml. A. fumigatus extracts showed even a much greater variability in the con-
centration of the major allergen Asp f1 within extracts from 8 companies ranging
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from less than 0.1 to 64 μg/ml. Obviously serologic and skin test investigations with
different extracts showing such a high variability even for the content of major aller-
gens will automatically generate discordant results. This was impressively shown
by a skin prick test study with four different commercial A. fumigatus extracts [25].
None of the four commercial skin prick test extracts was able to detect all of the 31
A. fumigatus-sensitised patients enrolled in the study.
Amongst the systems routinely used in the daily clinical practice, ImmunoCAP is
considered the “golden standard” for the in vitro determination of IgE [15]. Unfor-
tunately the extracts immobilised on ImmunoCAPs are not available as skin test
solution, hampering a direct correlation between in vitro and in vivo diagnostic out-
comes.
The most common systems routinely used for the determination of allergen-
specific IgE are the already mentioned ImmunoCAP system (Phadia, Uppsala,
Sweden), Immulite (DPC Los Angeles, USA), and ADVIA Centaur (Bayer
Healthcare, Tarrytwon, NY, USA). Comparative studies of the performance of these
systems have been reported and partly correlated with skin test outcomes [26–28].
Considering the clinical diagnosis of allergy as reference, sensitivity and specificity
of all in vitro IgE determination systems give comparable results. However both,
sensitivity and specificity varies between allergen extracts tested in all systems.
Notably, mould extract panels show identical sensitivity problems (>40%) for all
IgE assay systems [28]. The discrepant results between skin test, clinical history,
and mould-specific IgE is mainly due to the quality of the mould extracts used pro-
vided by different manufacturers [29].
4 Clinical Relevance of Serum IgE
Despite the fact that allergen-specific IgE immunoassays are promoted as tests for
“allergy diagnosis”, the only information provided by the tests relates to the pres-
ence or absence of allergen-specific IgE in serum. It is commonly agreed that the
presence of allergen-specific IgE is a prerequisite to develop allergic symptoms
against a given environmental allergenic source. However, up to more than 40% of
the subject with serum IgE to inhalant allergens did not present (respiratory) symp-
toms [30, 31] and therefore the in vitro determination of allergen-specific IgE is not
sufficient for a clinical diagnosis of allergy. The most reliable criterion for a clear
diagnosis of an allergy is still a clear correlation between exposure and symptoms
that can be derived, in many cases, from the clinical history. Obviously, the patient
has to provide the information to the clinician. This might be a relatively simple
story in the case of seasonal allergy like hay fewer, or exposure to animal dander.
The situation is not so easy in the case of mould allergy where the patient might or
might not be aware of the fact that he is exposed to fungal allergens and therefore
unable to provide useful information to the clinician.
Although the synthesis of allergen-specific IgE is required for the development of
allergic diseases we should not forget that the biologically active form of IgE is not
those present as soluble IgE in serum. Whether the presence of allergen-specific IgE
translates into clinical allergy depends on a complex interplay of multiple factors
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recently reviewed [31]. As stated in this review, there are many unanswered impor-
tant questions that need to be addressed in order to better understand how IgE sen-
sitisation translates into clinical allergy.
5 Conclusions
Whilst a clinical history is sufficient to identify causes and judge the severity of
most allergic diseases, sometimes the history is complex and, especially in poly-
sensitised patients many allergens may be involved. To identify the causative aller-
gens, assessments can be performed in vivo by skin tests or in vitro by measuring
allergen-specific serum IgE. Both methods strongly depend from the quality of the
extracts used and in this regard recombinant allergens can contribute to substan-
tially improve the diagnostic outcomes [32]. Compared to in vivo tests, in vitro
determination of allergen-specific IgE has the advantage to avoid allergen chal-
lenges which might elicit severe side effects or even induce a de novo sensitisa-
tion. Modern methods for the determination of serum IgE are reliable, reproducible,
and quantitative. They represent useful and suitable methods to screen large num-
bers of patients for potential allergies in clinical routine assessments. However,
one should be aware of the fact that, although propagated as methods for “allergy
diagnosis”, serum IgE-detection systems does not provide a direct evidence for
an allergy which always needs to be confirmed by clinical history, skin and/ or
provocation tests.
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